Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Hosted on MSN17d
Sanofi gets FDA approval for NovoLog insulin biosimilarrapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus. The FDA approved 3 mL single-patient-use prefilled pen and 10 mL ...
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), from Denmark’s Novo Nordisk, for the improvement of glycemic control in ...
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin ... patient-use prefilled pen and a 10-mL multiple-dose ...
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) ...
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog ... use prefilled pen and a 10-mL multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback